1. Home
  2. Analysis
  3. Cranberry
  4. Cefuroxime axetil

Cranberry vs. Cefuroxime axetil: side effect and effectiveness comparison (a real world drug study)

Summary:

We compare the side effects and drug effectiveness of Cranberry and Cefuroxime axetil. The phase IV clinical study is created by eHealthMe based on reports (from sources including the FDA) of 14,170 people who take Cranberry and Cefuroxime axetil, and is updated regularly.

What is Cranberry?

Cranberry has active ingredients of cranberry. It is often used in urinary tract infection. eHealthMe is studying from 5,399 Cranberry users. Check the latest studies of Cranberry.

What is Cefuroxime axetil?

Cefuroxime axetil has active ingredients of cefuroxime axetil. It is often used in sinusitis. eHealthMe is studying from 4,283 Cefuroxime axetil users. Check the latest studies of Cefuroxime axetil.

On Jul, 05, 2026

14,170 people who take Cranberry and Cefuroxime axetil are studied.

Cranberry vs Cefuroxime axetil drug comparison reports.

Drugs being compared in this study:

  • Cefuroxime Axetil (cefuroxime axetil)
  • Cranberry (cranberry)

Most common side effects of the drugs, overall:

Click here to view

Most common side effects of the drugs, in long term (1+ years) use:

Click here to view

Drug effectiveness:

Cranberry:

  • not at all: 2.3 %
  • somewhat: 18.01 %
  • moderate: 33.72 %
  • high: 23.75 %
  • very high: 22.22 %

Cefuroxime Axetil:

  • not at all: 5.23 %
  • somewhat: 33.14 %
  • moderate: 29.07 %
  • high: 26.16 %
  • very high: 6.4 %

Want to compare Cranberry with Cefuroxime axetil?

- Personalize this study to your gender and age (0-99+)

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of:

Browse all side effects of Cranberry:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Cefuroxime axetil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study is based on cranberry and cefuroxime axetil (the active ingredients of Cranberry and Cefuroxime axetil, respectively). Other drugs that have the same active ingredients (e.g. generic drugs or brand names) are also considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.